跳转至内容
Merck
CN

81129-M

EX-CYTE® Growth Enhancement Media Supplement

登录 查看组织和合同定价。

选择尺寸


关于此项目

eCl@ss:
32011401
UNSPSC Code:
12352200
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

form

liquid

shelf life

24 mo.

manufacturer/tradename

Ex-cyte®

Quality Level

Disclaimer

For further manufacturing use only. Not for human or animal consumption.

General description

Product Source: Bovine; Adult Bovine Serum

Preparation Note

refrigerated

Legal Information

EX-CYTE is a registered trademark of Merck KGaA, Darmstadt, Germany

存储类别

12 - Non Combustible Liquids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

商品

Learn more one the attenuated viral vaccines manufacturing process: cell culture, clarification, nuclease treatment, chromatography, and sterile filtration.

A custom-designed cost model is used to explore the economics of vaccine manufacturing across several different modalities including mRNA. The model enables greater process understanding, simulates bottlenecks, and helps to optimize production efficiency.

Influenza vaccines are commonly made using egg-based and cell-based manufacturing strategies. Find step-by-step information on the manufacturing process for each method.

This technical article breaks down the steps of upstream and downstream bioprocessing and formulation of virus-like particle vaccines.

相关内容

This technical article breaks down the adenovirus vaccine manufacturing process and provides a case study on developing an accelerated and cost-effective single-use adenoviral vector vaccine.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持